67 studies found for:    Open Studies | "Muscle Spasticity"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Muscle Spasticity"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Early Use of Botulinum Toxin in Spasticity Post Stroke.
Conditions: Stroke;   Muscle Spasticity;   Contracture
Interventions: Drug: onabotulinumtoxinA;   Drug: Placebo
2 Recruiting Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients
Conditions: Muscle Spasticity;   Multiple Sclerosis
Interventions: Biological: incabotulinumtoxinA;   Biological: Placebo
3 Unknown  Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
Condition: Muscle Spasticity Due to Multiple Sclerosis
Interventions: Drug: BGG492;   Drug: Placebo
4 Recruiting Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons
Condition: Muscle Spasticity as a Result of Spinal Cord Injury
Interventions: Drug: nabilone 0.5 mg;   Drug: placebo
5 Recruiting Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Conditions: Cerebral Palsy;   Spasticity
Interventions: Drug: IncobotulinumtoxinA (8 Units per kg body weight);   Drug: IncobotulinumtoxinA (6 Units per kg body weight);   Drug: IncobotulinumtoxinA (2 Units per kg body weight)
6 Recruiting Developing Optimal Focal Muscle Vibration for Improving Spasticity
Conditions: Vibration;   Electrophysiology;   Muscle Spasticity
Intervention: Device: Focal muscular vibration
7 Not yet recruiting Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: Sativex;   Drug: Placebo
8 Recruiting Reliability of an Algorithm to Diagnose Spasticity
Condition: Spasticity
Intervention:
9 Not yet recruiting Developing and Testing a Comprehensive MS Spasticity Management Program
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Behavioral: Spasticity: Take Control
10 Unknown  Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation
Conditions: Basal Energy Expenditure;   Spasticity
Intervention: Other: Weaning of Antispasticity Medication
11 Recruiting Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis
Condition: Spasticity
Interventions: Drug: Baclofen ER Capsules;   Drug: Placebo GRS
12 Recruiting Action of Baclofen Capsules in Spasticity Due to Multiple Sclerosis
Condition: Spasticity
Interventions: Drug: Baclofen dose 1;   Drug: Baclofen dose 2;   Drug: Placebo
13 Recruiting A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (Ms): An Open Label, Long Term, Safety Trial
Condition: Spasticity
Intervention: Drug: Baclofen
14 Recruiting SISTERS: Spasticity In Stroke Study - Randomized Study
Condition: Severe Spasticity
Intervention: Drug: intrathecal baclofen
15 Not yet recruiting ASIS for Botox in Upper Limb Spasticity
Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke;   Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12,;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
16 Recruiting BOTOX® Treatment in Pediatric Upper Limb Spasticity
Conditions: Pediatrics;   Muscle Spasticity;   Cerebral Palsy;   Stroke
Interventions: Biological: botulinum toxin Type A;   Drug: Normal Saline (Placebo)
17 Recruiting BOTOX® Treatment in Pediatric Lower Limb Spasticity
Conditions: Pediatrics;   Muscle Spasticity;   Cerebral Palsy
Interventions: Biological: botulinum toxin Type A;   Drug: Normal Saline (Placebo)
18 Recruiting OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Conditions: Muscle Spasticity;   Stroke
Interventions: Biological: onabotulinumtoxinA;   Drug: placebo (normal saline)
19 Recruiting BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Conditions: Pediatrics;   Muscle Spasticity;   Cerebral Palsy;   Stroke
Intervention: Biological: botulinum toxin Type A
20 Recruiting BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity
Conditions: Pediatrics;   Muscle Spasticity;   Cerebral Palsy
Intervention: Biological: botulinum toxin Type A

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years